Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Macimorelin - Aeterna Zentaris

Drug Profile

Macimorelin - Aeterna Zentaris

Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; JMARD-07; JMV-1843; Macimorelin acetate; Macrilen; Solorel

Latest Information Update: 15 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AEterna Zentaris Inc
  • Developer AEterna Zentaris Inc; Strongbridge Biopharma
  • Class Amides; Carboxylic acids; Diagnostic agents; Indoles; Oligopeptides; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase II Cachexia

Most Recent Events

  • 16 Jan 2019 Registered for Somatotropin deficiency (Diagnosis, In adults) in European Union, Norway, Iceland, and Liechtenstein (PO)
  • 27 Dec 2018 Macimorelin sub-licensed to Novo Nordisk in USA and Canada
  • 19 Nov 2018 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of macimorelin for Somatotropin deficiency (Diagnosis, In adults) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top